Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LILRB3/CD85a drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LILRB3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View LILRB3 Products |
| Gene Delivery | LILRB3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LILRB3 Products |
| Benchmark Ab | Anti-LILRB3 (Research Grade Reference Clone) Recombinant positive control. |
View LILRB3 Products |
| Validator | LILRB3 siRNA Set For knockdown verification. |
View LILRB3 Products |
| Related Target A | LILRB1 Critical for subfamily cross-reactivity and selectivity profiling. |
View LILRB1 Products |
| Related Target B | LILRB2 Synergistic myeloid checkpoint for combination therapy screening. |
View LILRB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening (LILRB1/2/4/5) | Homolog panel proteins strictly verified by mass spec and sequence analysis |
| Glycosylation-dependent binding | HEK293 Expressed (Native Glycosylation) to ensure proper folding |
| Lack of Controls | Research grade reference antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live LILRB3/CD85a R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LILRB3 therapeutics is intensifying, with major players shifting focus from traditional T-cell checkpoints to myeloid cell modulators. As first-generation myeloid therapies reach the clinic, the next wave of R&D is targeting highly selective LILRB3 antagonists to reprogram the tumor microenvironment without triggering pan-LILRB toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Emerging Biotech Innovators | Solid Tumors | Selectivity Assay (Need Homolog Panel Proteins) |
| Bispecific Antibody | Preclinical Phrama | Immuno-Oncology | Heterodimer Validation (Need Cross-reactive Abs) |
| Small Molecule | Academic Consortia | Autoimmune Disorders | Affinity Screening (Need High-Purity ECD-Fc) |